Dacomitinib can inhibit the growth and proliferation of PC cells by down-regulating FOXM1 and its downstream targets, such as polo-like kinase 1 (PLK1), survivin, cyclin B1 (CCNB1), c-Myc and aurora kinase B (AURKB) 283. This evidence concerns the gene PLK1 and pachyonychia congenita.